The 9:22 translocation fuses the Bcr gene with the Abl gene resulting in the expression of a chimeric protein, Bcr-Abl, that has an essential role in the molecular pathology of CML (Daley et al ...

Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor-risk subgroup of precursor B cell acute ...

BCR-ABL1 is a gene sequence that confirms the diagnosis of Chronic Myeloid Leukemia (CML), persistent bone marrow cancer. The detected gene is present in abnormal chromosome 22 of humans. In CML, part ...

These findings demonstrate that lipocalin 2 has at least two functions related to ... The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008. Abstract and Introduction Chronic Myeloid Leukemia ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion protein BCR-ABL1. The first-generation ABL tyrosine kinase inhibitor (TKI) ...

Single-nucleotide mutations in the BCR-ABL gene producing conformation changes in the BCR-ABL protein, which can affect the binding of imatinib to specific activation or kinase sites, can be ...

HQP1351 is a third-generation BCR-ABL inhibitor for the ... APG-1252 is one of the key drug candidates in Ascentage Pharma's pipeline that focuses on restoring cell apoptosis function and ...

BCR-ABL 35INS is an alternatively spliced BCR-ABL mRNA with a 35-bp insertion derived from intron 8 and positioned between the junction of ABL exons 8 and 9, resulting in a frameshift leading to the ...